Pfizer Buying Spree Continues With $5.4B Hematology Deal

August 8, 2022by Tom Murphy and Michelle Chapman, Associated Press
Pfizer Buying Spree Continues With $5.4B Hematology Deal
The Pfizer logo is displayed on the exterior of a former Pfizer factory, on May 4, 2014, in Brooklyn, New York. (AP Photo/Mark Lennihan, File)

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

Pfizer said Monday that the acquisition will boost its capabilities in rare hematology. Global Therapeutics makes Oxybryta tablets for treating sickle cell disease.

The latest deal follows Pfizer’s $11.6 billion acquisition of Biohaven, which the companies announced in May, and a $6.7 billion acquisition of Arena Pharmaceuticals announced last December.

Pfizer also announced in April a smaller acquisition to buy the privately held ReViral Ltd., which is developing a treatment for respiratory syncytial virus.

Pfizer Inc.’s top-selling COVID-19 vaccine and treatment have left the New York City drugmaker flush with cash to spend on an acquisition spree. The vaccine and treatment brought in more than $16 billion combined just in the recently completed second quarter.

Pfizer’s vaccine, Comirnaty, rang up nearly $37 billion in sales last year alone, but those sales are expected to fade in a few years. Pfizer also faces over the next decade the loss of patent protection for key products like Eliquis for preventing blood clots and strokes.

The company plans to have about $25 billion in sales by 2030 come from new business developments.

Aamir Malik, the company’s chief business innovation officer, told analysts recently that Pfizer was “leaving very few stones unturned” in looking for expansion opportunities. Malik said Pifzer was looking for deals that will speed up growth in the back half of the decade and can add substantial value either scientifically or commercially.

“I think we’re very excited about the opportunities that are ahead of us and the flexibility that our balance sheet gives us to pursue those,” he said during a call to discuss second-quarter results.

Aside from Oxbryta, Global Blood Therapeutics also is developing some other treatments for sickle cell disease.

Oxbryta sales were about $195 million last year, but Pfizer said it plans to speed up distribution of the drug to parts of the world most impacted by the disease.

Sickle cell disease is an inherited blood disorder that can lead to bouts of acute pain and organ damage. It occurs particularly among people of African descent.

Pfizer will pay $68.50 per share in cash for each share of Global Blood Therapeutics. That represents a premium of nearly 43% from the stock’s closing price of $47.99 on Aug. 4, the day before The Wall Street Journal reported that Pfizer was in advanced talks on a deal.

Both companies’ boards have approved the deal, which still needs regulatory approval and approval from GBT shareholders. The companies say the deal could close as soon as the fourth quarter.

Shares of Global Blood Therapeutics Inc., based just outside San Francisco, rose more than 4% to $66.68 before the opening bell. Shares of Pfizer were essentially flat.

___

Follow Tom Murphy on Twitter: @thpmurphy

A+
a-
  • Pfizer
  • In The News

    Health

    Voting

    Business

    March 15, 2024
    by Dan McCue
    DOE to Provide Conditional $2.26B Loan for Lithium Project in Nevada

    WASHINGTON — The Department of Energy is extending a conditional $2.26 billion loan to Lithium Americas Corp. to support its... Read More

    WASHINGTON — The Department of Energy is extending a conditional $2.26 billion loan to Lithium Americas Corp. to support its effort to build a lithium carbonate processing plant in Nevada. Once operational, the plant, which will be located in Thacker Pass, about 200 miles northeast of... Read More

    March 12, 2024
    by Dan McCue
    Charging Company Opens Global Headquarters in Maryland

    BOWIE, Md. — Blink Charging Co., one of the nation’s fast-growing makers of electric vehicle charging devices, celebrated the grand... Read More

    BOWIE, Md. — Blink Charging Co., one of the nation’s fast-growing makers of electric vehicle charging devices, celebrated the grand opening Monday of its 15,000 square-foot global headquarters in Bowie, Maryland. The site, along with a new, 30,000 square-foot LEED Gold-certified manufacturing site located within Melford... Read More

    Top Virginia Senate Negotiator Vows to Keep Alexandria Arena Out of the Budget

    RICHMOND, Va. (AP) — A top Democratic Virginia lawmaker vowed Wednesday to keep language enabling a proposed relocation by the... Read More

    RICHMOND, Va. (AP) — A top Democratic Virginia lawmaker vowed Wednesday to keep language enabling a proposed relocation by the NBA’s Washington Wizards and NHL’s Washington Capitals to Alexandria out of the state budget lawmakers will take up later this week. Sen. L. Louise Lucas, who... Read More

    Candy Companies Pitch Gum as Stress Reliever and Concentration Aid to Revive Stale Sales

    Candy companies want to know: What will make Americans start chewing gum again? Gum’s bubble burst during the COVID-19 pandemic, when masks... Read More

    Candy companies want to know: What will make Americans start chewing gum again? Gum’s bubble burst during the COVID-19 pandemic, when masks and social distancing made bad breath less of a worry and fewer people spent on impulse buys. The number of packages of gum sold dropped by nearly a... Read More

    March 4, 2024
    by Tom Ramstack
    Attorneys in Tesla Lawsuit Seek $6B in Legal Fees

    WILMINGTON, Del. — Attorneys who succeeded in getting a Delaware court to void Elon Musk's $55 billion compensation package from... Read More

    WILMINGTON, Del. — Attorneys who succeeded in getting a Delaware court to void Elon Musk's $55 billion compensation package from Tesla, Inc. on Friday asked the court for about $6 billion in legal fees.  They want most of their money paid in Tesla stock, which would... Read More

    February 16, 2024
    by Dan McCue
    Trump Ordered to Pay $355M for Fraud in New York Civil Trial

    WASHINGTON — Former President Donald Trump must pay a penalty of $355 million for fraudulently overstating his wealth, a penalty... Read More

    WASHINGTON — Former President Donald Trump must pay a penalty of $355 million for fraudulently overstating his wealth, a penalty that could effectively leave him with little, if any, actual cash on hand. The ruling by Manhattan Supreme Court Justice Arthur Engoron also imposes a three-year... Read More

    News From The Well
    scroll top